Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials.
Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.
Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
The British journal of dermatology·2021
Ethosuximide-induced lupus erythematosus: Unveiling a rare adverse reaction through systematic review.
Epilepsy & behavior reports·2026
Autoimmune thyroiditis in pregnancy: epidemiology, clinical impact, and contemporary management challenges.
Journal of medicine and life·2026